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AIMS
CYP2D6*9, CYP2D6*10 and CYP2D6*41 are the most frequent reduced-function CYP2D6 alleles in Caucasians. Despite lacking
in vivo evidence, they are collectively classiﬁed with an enzyme activity score of 0.5. Thus, the aim of this study was to compare the
functional impact of CYP2D6*9, CYP2D6*10 and CYP2D6*41 on CYP2D6 metabolism in a large patient population.
METHODS
A total of 1003 patients (mainly Caucasians) with data on CYP2D6 genotype and serum concentrations of venlafaxine and
metabolites were included from a therapeutic drug monitoring service in Oslo, Norway. The O-desmethyl-to-N-desmethyl-
venlafaxine metabolic ratio (MR) was applied as CYP2D6 biomarker and compared (Mann–Whitney) between carriers of
CYP2D6*9–10 (merged) and CYP2D6*41, either combined with CYP2D6*1 or non-coding (null) alleles. MR subgroup estimates
were obtained by multiple linear regression for calculations of CYP2D6*9–10 and CYP2D6*41 activity scores.
RESULTS
MR was signiﬁcantly lower in carriers of CYP2D6*41 than CYP2D6*9–10 (P < 0.002). The majority of CYP2D6*41/null carriers
(86.7%) had MR in the observed range of CYP2D6null/null carriers compared with the minority of CYP2D6*9–10/null carriers
(17.4%). CYP2D6 genotype explained 60.7% of MR variability in the multivariate analysis providing subgroup estimates of 9.54
(95% CI; 7.45–12.20), 3.55 (2.06–6.10), 1.33 (0.87–2.05) and 0.47 (0.35–0.61) in carriers of CYP2D6*1/null (n = 269),
CYP2D6*9–10/null (n = 17), CYP2D6*41/null (n = 30) and CYP2D6null/null (n = 95), respectively. Based on these estimates, the
calculated activity score of CYP2D6*41 was 0.095 compared to 0.34 for CYP2D6*9–10.
CONCLUSIONS
CYP2D6metabolismmeasured as theO/N-desmethylvenlafaxine ratio is signiﬁcantly lower in Scandinavian carriers of CYP2D6*41
vs. CYP2D6*9–10. Thus, these alleles should be differentiated when classifying CYP2D6 phenotype from genotype.
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WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
• CYP2D6 is the most relevant polymorphic drug-metabolizing enzyme.
• CYP2D6 phenotype closely relates to genotype, and allelic activity scores are used when interpreting individual pheno-
type based on CYP2D6 genotype.
• The most common CYP2D6 variant alleles encoding reduced metabolism in Caucasians, i.e. CYP2D6*9, CYP2D6*10 and
CYP2D6*41, are collectively classiﬁed with an activity score of 0.5 without evidence from in vivo studies. Thus, it is impor-
tant to quantify and compare their impact on CYP2D6 phenotype.
WHAT THIS STUDY ADDS
• CYP2D6 phenotype, as measured by the O/N-desmethylvenlafaxine metabolic ratio in therapeutic drug
monitoring samples from a large Scandinavian population, is signiﬁcantly lower in carriers of CYP2D6*41 than
CYP2D6*9–10.
• The study suggests a residual CYP2D6-metabolizing activity score of 0.095 for CYP2D6*41 compared with 0.34 for
CYP2D6*9–10, which illustrates the importance of differentiating between these alleles when studying the effect of
CYP2D6 genotype on pharmacokinetics and therapeutic response of CYP2D6 substrates.
• As >80% of CYP2D6*41/null carriers had O/N-desmethylvenlafaxine metabolic ratios in the observed range of
CYP2D6null/null carriers (poor metabolizers), this subgroup is particularly important to be aware of when interpreting
CYP2D6 phenotype from genotype.
Introduction
Cytochrome P450 2D6 (CYP2D6) is the most relevant poly-
morphic enzyme involved in drug metabolism. A large
proportion of clinically used drugs (>200) are substrates of
CYP2D6 [1], and the inherent multimodality in metabolizer
phenotype results in a substantial inter-individual variabil-
ity in exposure and therapeutic response at similar dosing
of the affected agents; e.g. many psychotropic drugs, opioid
analgesics and beta blockers [1–4]. More than 100 different
CYP2D6 variant alleles have been described, which may
cause reduced, absent, increased or unchanged enzyme
activity, and their frequencies are often dependent on
ethnicity [5].
CYP2D6 metabolizer status is divided into four different
phenotype subgroups, i.e. poor metabolizers (PMs), inter-
mediate metabolizers (IMs), extensive (normal) metabolizers
(EMs/NMs) and ultrarapid metabolizers (UMs) [6]. When
classifying CYP2D6 phenotype from genotype, homozygous
carriers of non-coding variant alleles (null alleles) are
deﬁned as PMs, while carriers of two reduced-function alleles
or one reduced-function and one null allele are merged into
a common group of IMs [5]. Individuals carrying >2 fully
functional gene copies are deﬁned as CYP2D6 UMs, and
the remaining, who possess at least one fully functional
CYP2D6 allele, are classiﬁed as EMs/NMs [6]. However,
except for CYP2D6 PMs, there is substantial variability in
CYP2D6 phenotypes within the respective subgroups, and
Hertz et al. recently reported that the subgroup of IMs
probably should be further reﬁned based on CYP2D6
genotype [7].
In Caucasian populations, CYP2D6*9, *10 and *41 are
the most common reduced-function variant alleles [5]. These
are collectively classiﬁed with activity score of 0.5 [2, 5, 8],
despite lack of in vivo data comparing their quantitative
effect on CYP2D6 metabolism. The CYP2D6*41 allele is of
particular interest in Caucasians, due its high allele
frequencies in many European countries [9]. An in vitro study
showed an 85% reduction in enzyme activity encoded by
CYP2D6*41 compared with wild-type CYP2D6*1 allele [10].
Reports by Abduljalil et al. [11] and Gazzaz et al. [12] have
also indicated a low in vivo metabolizer function in
CYP2D6*41 carriers, but these included a limited number
of subjects. Studies of sufﬁcient size evaluating the enzyme
activity reduction in CYP2D6*41 carriers are therefore
lacking.
CYP2D6 genotyping is increasingly implemented in clin-
ical routine as a tool for assessment of therapeutic failure or
start-of-treatment dose estimations of CYP2D6-metabolized
drugs [9, 13, 14]. Thus, the accuracy of genotype–phenotype
interpretations becomesmore crucial, as this has direct impli-
cations for patient treatment. Diplotype activity scores are
used when interpreting CYP2D6 phenotype from genotype
[2, 5, 15, 16], which implicates the clinical relevance of
correct allelic activity score assessments.
Assessments of allelic activity scores require a sensitive
and speciﬁc CYP2D6 metric (biomarker), which is practical
to study in large populations. Recently, we showed that the
ratio between the O- and N-desmethylated metabolites of
venlafaxine is a well-suited CYP2D6 biomarker by detect-
ing genotype-predicted PMs with a speciﬁcity and sensitivity
of >85% using a predeﬁned cutoff ratio in a naturalistic
setting [17]. Venlafaxine undergoes highly speciﬁc
CYP2D6-mediated O-desmethylation as the major metabolic
pathway [18], implying that CYP2D6 phenotype also
indirectly regulates metabolite formation via the secondary
N-desmethylation pathway.
As venlafaxine is a commonly used antidepressant with
frequent serum concentration monitoring of drug and me-
tabolites, the O/N-desmethylvenlafaxine metabolic ratio of-
fers the possibility of evaluating the impact of CYP2D6
variant alleles on metabolizer phenotype by matching geno-
type and biomarker data available from therapeutic drug
monitoring (TDM). Thus, the aim of the present study was
to compare the functional impact of the reduced-function
variant alleles CYP2D6*9, CYP2D6*10 and CYP2D6*41 on
CYP2D6 phenotype in a big Scandinavian TDM cohort of
venlafaxine-treated patients.
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Methods
Patient inclusion
Patients were retrospectively included from a TDM service at
the Center for Psychopharmacology, Diakonhjemmet
Hospital, Oslo, Norway, if they had performed (i) CYP2D6
genotyping, and (ii) measured serum concentration(s) of
venlafaxine, including O- and N-desmethylated metabolites,
as part of clinical routine. For serum concentration measure-
ments, only patients with a time interval of 10–26 h between
last dose intake of venlafaxine and blood sampling for
analysis were included.
A search in the TDMdatabase (Swisslab II, Roche Diagnos-
tics, Berlin, Germany) was performed to identify patients
fulﬁlling inclusion criteria during the period from September
2007 to October 2017. Data retrieved from the database
search also comprised information about sex, age (at the time
of venlafaxine TDM), prescribed daily dose of venlafaxine,
and time between last dose intake and blood sampling for
serum concentration analysis within the required 10–26 h in-
terval. Although ethnicity was unknown, as this information
is not registered and stored during TDM for legal reasons, the
population mainly comprised Caucasians from the general
ethnic composition in Norway. Information about
comedicated drugs was obtained from information provided
on the TDM requisition forms, which were reviewed for all
patients identiﬁed in the database search. Patients concur-
rently using the potent CYP3A inducers carbamazepine,
phenobarbital or phenytoin, or the potent CYP2D6
inhibitors bupropion, ﬂuoxetine, levomepromazine
(>50 mg day1) or paroxetine, were excluded.
The study was approved by the Regional Committee for
Medical and Health Research Ethics, and the Hospital Investi-
gational Review Board. Ethical approval was given without
requirement for patient consent as the study was based on
existing data retrospectively retrieved from a routine TDM
service.
CYP2D6 genotype
Analyses of CYP2D6 variant alleles were performed using
Taqman-based real-time PCR assays implemented for routine
pharmacogenetic analyses at the Center for Psychopharma-
cology, Diakonhjemmet Hospital. The CYP2D6 pharmacoge-
netic panel included the null alleles CYP2D6*3
(rs35742686), CYP2D6*4 (rs3892097), CYP2D6*5 (whole
gene deletion) and CYP2D6*6 (rs5030655), the reduced-
function variants CYP2D6*9 (rs5030656), CYP2D6*10
(rs1065852) and CYP2D6*41 (rs28371725), as well as copy
number analysis to identify multiplication of functional
alleles giving rise to ultrarapid metabolism. It has been
established that the contribution of unknown rare genetic
variants to inter-individual variation in CYP2D6 activity is
limited [19], so the genotyping panel covered at least 95%
of the variant CYP2D6 alleles of relevance for CYP2D6 phe-
notype in the population.
Due to the separately low frequencies of CYP2D6*9 and
CYP2D6*10, and initial assessments showing no differences
in MR between comparable subgroups (P > 0.1;
Mann–Whitney), these variants were merged to form a
CYP2D6*9–10 grouping in all further assessments in the
study. Prior to statistical analyses, the patients were divided
into the following subgroups according to CYP2D6 genotype:
CYP2D6*1/*1 (absence of variants detected in the assays),
CYP2D6*1/*9–10, CYP2D6*1/*41, CYP2D6*1/null,
CYP2D6*9–10/*9–10, CYP2D6*9–10/*41, CYP2D6*41/*41,
CYP2D6*9–10/null, CYP2D6*41/null, and CYP2D6null/null
(i.e. poor metabolizers; PMs). In addition, patients detected
with more than two fully functional CYP2D6 alleles
(CYP2D6*1/*1XN) were deﬁned as ultrarapid metabolizers
(UMs), while those with more than two gene copies and
concurrent detection of null or reduced-function CYP2D6
variant alleles were undeﬁned and excluded before statistical
analysis.
CYP2D6 phenotype
The O-desmethyl-to-N-desmethylvenlafaxine (O/N-
desmethylvenlafaxine) metabolic ratio (MR) was used as
CYP2D6 phenotype biomarker to compare the functional
impact of CYP2D6*9–10 and CYP2D6*41 in the study popu-
lation. The appropriateness of the biomarker for this purpose
was supported by a previous study showing that genotyped
PMs were detected with a speciﬁcity and sensitivity of 87%
and 93%, respectively [17].
Serum concentrations of O-desmethyl- and N-
desmethylvenlafaxine were analysed as a part of TDM of
venlafaxine at the Center for Psychopharmacology,
Diakonhjemmet Hospital. The analytical method was carried
out by use of an ultraperformance liquid chromatography-
mass spectrometry (UPLC-MS/MS) assay with inter- and
intra-day imprecision and inaccuracy parameters <10% [17].
Statistical analyses
In the initial assessment, unadjusted measurements of
O/N-desmethylvenlafaxine MRs in CYP2D6*1/*9–10 vs.
CYP2D6*1/*41 carriers, and CYP2D6*9–10/null vs.
CYP2D6*41/null carriers, were compared by univariate
Mann–Whitney tests. Then, a multiple linear regression
analysis was performed to provide covariate-adjusted MR
estimates of all genotype subgroups. Covariates included in
the multiple linear regression analysis were sex, age, pre-
scribed daily dose of venlafaxine, and time between drug in-
take and blood sampling (within the inclusion criterion
interval of 10–26 h). Log-transformedMR values were applied
in the multiple linear regression analysis, but the provided
genotype subgroup estimates (geometric means) were
backtransformed for data presentation and calculation of
activity scores of CYP2D6*9–10 and CYP2D6*41.
Statistical analyses were performed using IBM SPSS
Software version 22.0 (IBM Corp., Armonk, New York), and
P values <0.05 deﬁned as statistically signiﬁcant. GraphPad
Prism version 5 (GraphPad Software Inc., La Jolla, California)
was used for graphical presentations.
Calculation of activity scores of CYP2D6*9–10
and CYP2D6*41
When calculating the residual enzyme activity scores of
CYP2D6*41 and CYP2D6*9–10, the covariate-adjusted MR
estimates from the multiple linear regression analysis were
applied. Since only the enzyme activity encoded by
CYP2D6null alleles is certain (0%), the activity scores of
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CYP2D6*9–10 and CYP2D6*41 were calculated by relating
MR estimates in carriers of CYP2D6*9–10/null and
CYP2D6*41/null on a linear scale deﬁning the MR of
CYP2D6null/null carriers as score ‘0’ and the MR of
CYP2D6*1/null carriers as score ‘1’. Hence, the following
formula was applied to calculate the respective activity scores
(AS) of CYP2D6*9–10 and CYP2D6*41, denominated ‘X’:
MR CYP2D6X=nullMR CYP2D6null=nullð Þ=
MR CYP2D61=nullMR CYP2D6null=nullð Þ ¼ AS of X
Nomenclature of targets and ligands
Key protein targets and ligands in this article are
hyperlinked to corresponding entries in http://www.
guidetopharmacology.org, the common portal for data from
the IUPHAR/BPS Guide to PHARMACOLOGY [20], and are
permanently archived in the Concise Guide to PHARMA-
COLOGY 2017/18 [21].
Results
Study population
After excluding 14 patients concurrently using venlafaxine
with either potent CYP2D6 inhibitors (bupropion, n = 5;
levomepromazine, n = 4; ﬂuoxetine, n = 2) or CYP3A inducers
(carbamazepine, n = 2; phenytoin, n = 1), a total of 1021
patients who had performed both CYP2D6 genotyping and
serum concentration analysis of venlafaxine and metabolites
(within the deﬁned time interval of 10–26 h from last dose
intake) were included from the TDM database search. Among
these, 18 patients were genotyped with more than two gene
copies and concurrent detection of null (CYP2D6*4) or
reduced-function (CYP2D6*41) variant alleles and excluded
before statistical analysis. Thus, 1003 patients were
included for comparison of the functional impact of
CYP2D6*9, CYP2D6*10 and CYP2D6*41 on the O/N-
desmethylvenlafaxine MR.
CYP2D6 genotype distribution. The CYP2D6 genotype
distribution in the population is presented in Table 1. The
proportion of CYP2D6null/null carriers in the patient
population was 9.3% (95% CI 7.7–11.3%). Among the
reduced-function variant alleles, CYP2D6*41 was most
commonly detected in the study population (allele
frequency 6.6%), and found in combination with
CYP2D6null alleles in 2.9% of the patients (95%CI 2.1–4.2%).
The proportions of homozygous carriers of CYP2D6null
alleles and CYP2D6*10 alleles were both higher than
indicated from their respective allele frequencies, and hence
not found to be in Hardy–Weinberg equilibrium (P < 0.05).
For all other variants, no deviation from Hardy–Weinberg
equilibrium was detected (P > 0.1). All patients with in-
creased copy number of functional CYP2D6 alleles were trip-
licate carriers.
Metabolic ratios in carriers of CYP2D6*41 vs. CYP2D6*9–10.
Figure 1 shows scatterplots of unadjusted MRs in the
included patients according to CYP2D6 genotype. Patients
Table 1
CYP2D6 genotype distribution in the study population (n = 1021)
Genotype Number of patients Proportion 95% conﬁdence interval
CYP2D6*1/*1 413 0.4045 0.3748–0.4349
CYP2D6*1/*9 51 0.0500 0.0381–0.0652
CYP2D6*1/*10 9 0.0088 0.0044–0.0169
CYP2D6*1/*41 74 0.0725 0.0580–0.0901
CYP2D6*1/null 269 0.2635 0.2374–0.2914
CYP2D6*9/*9 2 0.0020 <0.0001–0.0076
CYP2D6*10/*10 5 0.0049 0.0017–0.0118
CYP2D69–10/*41 8 0.0078 0.0037–0.0157
CYP2D6*41/*41 7 0.0069 0.0030–0.0144
CYP2D6*9/null 11 0.0108 0.0058–0.0194
CYP2D6*10/null 6 0.0059 0.0024–0.0131
CYP2D6*41/null 30 0.0294 0.0205–0.0418
CYP2D6null/null 95 0.0930 0.0767–0.1125
CYP2D6*1/*1XN 23 0.0225 0.0149–0.0337
CYP2D6*1/*4XN or *1/*41XNa 18 0.0176 0.0110–0.0278
aPatient subgroup excluded in the study due to unknown identity of the duplicated allele
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with CYP2D6*1/*41 had signiﬁcantly lower median MR than
CYP2D6*1/*9 or CYP2D6*1/*10 carriers (P < 0.001), and the
same difference was observed for CYP2D6*41/null vs.
CYP2D6*9–10/null carriers (P = 0.002). In CYP2D6*41/null
carriers (n = 30), MRs of 26 patients (86.7%) were in the
range of CYP2D6null/null carriers compared to only three
out of 17 carriers of CYP2D6*9–10/null (17.4%) (Figure 2).
In line with the initial univariate statistical analyses,
results of the multiple linear regression analysis showed
consistently lower covariate-adjustedMR estimates in carriers
of CYP2D6*41 than CYP2D6*9–10 with comparable allele
combinations (Table 2). The covariate-adjusted MR estimate
of the CYP2D6*41/null subgroup (MR 1.33) was closer to the
CYP2D6null/null subgroup (MR 0.47) than all other geno-
types, and the MR estimate in CYP2D6*41/*41 carriers was
similar to CYP2D6*9–10/null carriers (Table 2). Moreover,
the covariate-adjusted MR subgroup estimates were similar
in patients with CYP2D6*9–10/*41, CYP2D6*9–10/*9–10 or
CYP2D6*1/null genotypes (Table 2).
In the multiple linear regression analysis, CYP2D6
genotype alone explained 60.7% of the variability in MR
(aR2 = 0.607) underscoring the suitability of O/N-
desmethylvenlafaxine as a CYP2D6 phenotype biomarker.
When including covariates in the multivariate model (sex,
age, venlafaxine dose, and sampling time within 10–26 h
after last dose intake), the explained variability in MR was
only marginally increased (R2 = 0.638).
Activity scores of CYP2D6*41 and CYP2D6*9–10. When
calculating the residual enzyme activity scores of
CYP2D6*41 and CYP2D6*9–10, the covariate-adjusted MR
estimates in CYP2D6*41/null (n = 30; MR 1.33) and
CYP2D6*9–10/null (n = 17; MR 3.55) subgroups,
respectively, were related those of CYP2D6null/null (n = 95;
MR 0.47), and CYP2D6*1/null (n = 269; MR 9.54) carriers.
On a linear scale deﬁning the MR estimate in CYP2D6*1/
null carriers as ‘1’ and the MR estimate in CYP2D6null/null
carriers as ‘0’, the activity score of CYP2D6*41 was 0.095
(9.5% residual enzyme activity) compared to 0.34 (34%
residual enzyme activity) of CYP2D6*9–10.
Figure 1
Scatterplots of directly measured, unadjusted,O/N-desmethyl-venlafaxine metabolic ratios (MR) in patients with various CYP2D6 genotypes (lines
indicate median values). P-values are from Mann–Whitney tests comparing MRs in CYP2D6*1/*9–10 vs. CYP2D6*1/*41 carriers, and CYP2D6*41/
null vs. CYP2D6*9–10/null carriers, respectively
Figure 2
Frequency histogram showing overlaps in CYP2D6 phenotypes, i.e.
measured O/N-desmethylvenlafaxine metabolic ratios (MR),
between patients carrying CYP2D6null/null, CYP2D6*41/null or
CYP2D6*9–10/null genotypes
T. Haslemo et al.
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Discussion
To the best of our knowledge, this is the ﬁrst study to
compare the functional impact of CYP2D6*9, CYP2D6*10
and CYP2D6*41 on in vivo CYP2D6 metabolism. These are
the most frequent reduced-function CYP2D6 variant alleles
in Caucasians, and the present study shows that carriers
of CYP2D6*41 consistently exhibit substantially lower
CYP2D6 metabolism, as measured by the O/N-
desmethylvenlafaxine metabolic ratio, than comparable
carriers of CYP2D6*9 or CYP2D6*10. While the residual
activity score of CYP2D6*41 was only 9.5%, the score of
CYP2D6*9–10 was approximately three-fold higher.
Contrary to current recommendations deﬁning activity
scores of all three variants by 0.5 [2, 5, 8], it is therefore cru-
cial to differentiate between these alleles when interpreting
CYP2D6 phenotype from genotype.
The low activity score of CYP2D6*41 calculated in the
present study of mainly Caucasians is supported by previous
reports by Abduljalil et al. [11] and Gazzaz et al. [12]. However,
these prior studies included a very limited number of
CYP2D6*41 carriers (nine in total), with only one [11] and
two [12] subjects being CYP2D6*41/null carriers, respectively.
In comparison, the present study comprised a large number
of patients carrying the CYP2D6*41/null genotype (n = 30).
Among CYP2D6*41/null carriers in our study, more than
80% displayed O/N-desmethylvenlafaxine metabolic ratios
within the observed range CYP2D6null/null carriers, while
this was the case for<20% of CYP2D6*9–10/null carriers. This
is in line with the greater impact of CYP2D6*41 than
CYP2D6*9–10 on CYP2D6 phenotype, which should provide
a basis for discussing the current genotype-based classiﬁca-
tion of CYP2D6 IMs.
Current guidelines merge genotypes homozygous for any
reduced-function alleles, as well as genotypes comprising one
reduced-function and one null allele, into a common group
of IMs [6]. However, the covariate-adjusted MR subgroup
estimates of the present study indicate that carriers of
CYP2D6*41/null may represent an intermediate-to-poor me-
tabolizing (IPM) phenotype, while carriers of CYP2D6*9–10/
null or CYP2D6*41/*41 generally display lower CYP2D6 me-
tabolism than carriers of CYP2D6*9–10/*41, CYP2D6*9–10/
*9–10 or CYP2D6*1/null. Thus, more reﬁned genotype-based
IM subgroup classiﬁcations should be considered in future
studies investigating the effect of CYP2D6 genetics on
pharmacokinetics or clinical outcomes of candidate drugs;
e.g. the prodrug tamoxifen, where CYP2D6 metabolizer
phenotype could be of critical importance for the therapeutic
response [22–25].
Mutations described by Raimundo et al. in 2000 led to the
identiﬁcation of the CYP2D6*41 variant allele [26], which is
believed to result in reduced enzyme expression due to a
splicing defect [10, 27]. Our study consistently shows that
carriers of rs28371725 (c.985 + 39G>A; denoted as
‘CYP2D6*41’) exhibit signiﬁcantly lower CYP2D6 metabo-
lism, as measured by the O/N-desmethylvenlafaxine meta-
bolic ratio, than carriers of CYP2D6*9 or CYP2D6*10. Thus,
rs28371725 in CYP2D6*41 is clearly a marker of the substan-
tially reduced CYP2D6 metabolism in our study population,
and possibly causative for the decreased expression of
CYP2D6*41 by producing a splicing defect [10, 27]. However,
it could not be excluded that other mutations in linkage
disequilibrium with CYP2D6*41 may play a role in the
phenotype effect, as indicated in a study by Wang et al. [28].
Furthermore, our population comprised Scandinavians of
mainly Caucasian origin, implying that the calculated
CYP2D6*41 activity score might be different in other popula-
tions due to interethnic haplotype variability. The same point
also applies for CYP2D6*9–10, and another aspect is that the
impact of CYP2D6*41 vs. CYP2D6*9–10 on the metabolic
proﬁle of other drugs than venlafaxine could be different.
Therefore, it is important to further investigate the relative
impact of these variant alleles for CYP2D6 metabolism in
various ethnic groups, focusing on the potential relevance
of haplotype differences and substrate diversity in large study
populations.
The O/N-desmethylvenlafaxine MR was recently shown
to have a high speciﬁcity and sensitivity (>85%) in detect-
ing genotype-predicted CYP2D6 PMs [17]. In the present
study on more than 1000 patients, CYP2D6 genotype alone
explained 60.7% of the variability in the MR when
accounting for signiﬁcant covariates in the multiple linear
regression analysis. As CYP2D6 genotype and phenotype is
known to be closely correlated, this underscores the suitabil-
ity of O/N-desmethylvenlafaxine MR as a CYP2D6 biomarker
for comparing the functional impact of different variant
alleles. The prescribed venlafaxine dose and sampling time
Table 2
Estimated metabolic ratios (MR) of O-desmethyl/N-desmethyl-
venlafaxine in different CYP2D6 genotype subgroups from multiple
linear regression analysis adjusting for covariates (n = 1003). R2
adjusting for covariatesa = 0.638; R2 with CYP2D6 genotype as only
independent variable = 0.607
Genotype MR estimateb 95% conﬁdence interval
CYP2D6null/null 0.47 0.35–0.61
CYP2D6*41/null 1.33 0.87–2.05
CYP2D6*9–10/null 3.55 2.06–6.10
CYP2D6*41/*41 3.92 1.75–8.78
CYP2D6*9–10/*41 8.54 3.97–18.38
CYP2D6*9–10/*9–10 9.12 4.07–20.41
CYP2D6*1/null 9.54 7.45–12.20
CYP2D6*1/*41 14.67 10.64–20.22
CYP2D6*1/*9–10 27.16 19.31–38.22
CYP2D6*1/*1 36.83 29.13–46.56
CYP2D6*1/*1XN 68.18 42.21–110.13
aCovariate effects: (i) gender +0.16 in MR for males vs. females
(P < 0.001), (ii) time between last dose intake and blood sampling
+0.08 in MR per hour from 10–26 h (P = 0.009), and (iii) dose
0.015 in MR per 10 mg day1 (P < 0.001). No effect of age on
MR, included as continuous or grouped ≥65 vs. <65 years (P> 0.7)
bThe multiple linear regression analysis was performed with log-
transformed MR values, but the tables comprise back-transformed
geometric mean estimates with 95% conﬁdence interval (CI)
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point (within 10–26 h) only had minor quantitative effects
on the MR, indicating fairly similar relative formation by
dose and elimination kinetics of the two venlafaxine
metabolites.
Despite highly signiﬁcant MR differences between the
genotype subgroups, there was also considerable intra-
subgroup variability in phenotypes, probably reﬂecting a
combination of additional genetic and non-genetic factors
affecting venlafaxine metabolism. Some of the variability
was likely due to the presence of CYP2D6 variants not in-
cluded in the genotyping panel of the study, e.g. CYP2D6*35,
which has been associated with increased CYP2D6 metabo-
lism [29]. Another variant not included in the panel was
CYP2D6*2, an allele generally assigned to encode ‘normal’
enzyme activity [30], but where some studies have reported
a reduced CYP2D6 phenotype as well [11]. In a recent review
article by Gaedigk et al., it was further pointed out that other
sources than CYP2D6 genotype likely contribute to the
variability in CYP2D6-mediated drug metabolism [15]. While
O-desmethylation of venlafaxine is CYP2D6-speciﬁc,
CYP3A4 and CYP2C19 are both involved in the
N-desmethylation pathway [31]. Thus, individual differences
in CYP3A4 and/or CYP2C19 metabolism may also to some
extent contribute to the intra-subgroup MR variability.
Furthermore, the individual differences in activities of the
enzymes involved in the N-desmethylation pathway of
venlafaxine may potentially limit the linear MR scaling over
a large interindividual range when calculating the CYP2D6
alleles’ activity scores.
The present study has some limitations related to the
naturalistic design and heterogeneous nature of included pa-
tients. Although the TDM requisition forms were thoroughly
reviewed to identify and exclude users of potent CYP2D6
inhibitors or CYP3A4 inducers, the comedication proﬁles
written on the forms might be incomplete, implying that
some patients were using drugs (or herbal agents) affecting
the MR. Another issue was that ethnicity of the patients was
not available from the TDM records. Despite the majority
being Caucasians, the deviation of CYP2D6*10 from
Hardy–Weinberg equilibrium likely reﬂects an ethnic hetero-
geneity of the population, which was supported by name
attributes on the TDM requisition forms indicating Asian
descent of the three homozygous carriers of CYP2D6*10.
Regarding the higher frequency of patients carrying the
CYP2D6null/null genotype, i.e. 9.3%, compared to healthy
Caucasians [1, 4, 32], a likely explanation is patient inclusion
from a naturalistic TDM setting, where cases with therapeutic
problems and a poor metabolizer phenotype might be
overrepresented. Thus, it is important to be aware that the
detected frequency of CYP2D6*41/null carriers in the study
population (2.9%) is probably higher than in Caucasian
populations in general.
In conclusion, this study shows that CYP2D6 metabolism
measured as the O/N-desmethylvenlafaxine ratio is
signiﬁcantly lower in Scandinavian carriers of CYP2D6*41
than CYP2D6*9–10. Our ﬁndings in a large population
suggest that the residual enzyme activity score of CYP2D6*41
is only 9.5% of normal compared to 34% for CYP2D6*9–10 in
subjects of mainly Caucasian origin. Thus, these variant
alleles should be differentiated when classifying CYP2D6
phenotype from genotype.
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